No profile data available.
Nika Pharmaceuticals, INC (NIKA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Henderson, United States.
It reported revenue of $0 for fiscal year 2025, and net income of -$76,398. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $429.91 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products.
Nika Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$429.91 million as of October 8, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Altimmune, Inc. (ALT), Contineum Therapeutics, Inc. (CTNM), Kamada Ltd. (KMDA), Emergent BioSolutions Inc. (EBS).